197 related articles for article (PubMed ID: 36266631)
41. Comparison of Model-Free and Model-Based Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Parameters for Predicting Breast Cancers' Response to Neoadjuvant Chemotherapy.
Lv G; Zhou Y; Zheng D; Gao J; Xu Z; Jiang L
J Comput Assist Tomogr; 2020; 44(2):269-274. PubMed ID: 32195807
[TBL] [Abstract][Full Text] [Related]
42. Multiple parameters from ultrafast dynamic contrast-enhanced magnetic resonance imaging to discriminate between benign and malignant breast lesions: Comparison with apparent diffusion coefficient.
Cao Y; Wang X; Shi J; Zeng X; Du L; Li Q; Nickel D; Zhou X; Zhang J
Diagn Interv Imaging; 2023 Jun; 104(6):275-283. PubMed ID: 36739225
[TBL] [Abstract][Full Text] [Related]
43. Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI.
Savaridas SL; Vinnicombe SJ; Warwick V; Evans A
Br J Radiol; 2023 Aug; 96(1148):20220921. PubMed ID: 37399083
[TBL] [Abstract][Full Text] [Related]
44. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
46. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer.
Dogan BE; Yuan Q; Bassett R; Guvenc I; Jackson EF; Cristofanilli M; Whitman GJ
Curr Probl Diagn Radiol; 2019; 48(3):235-240. PubMed ID: 29685400
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the Relationship Between Dynamic Contrast-Enhanced MRI (DCE-MRI) Parameters and Pathological Characteristics in Breast Cancer.
Kang SR; Kim HW; Kim HS
J Magn Reson Imaging; 2020 Nov; 52(5):1360-1373. PubMed ID: 32524658
[TBL] [Abstract][Full Text] [Related]
48. Integrating dynamic contrast-enhanced magnetic resonance imaging and diffusion kurtosis imaging for neoadjuvant chemotherapy assessment of nasopharyngeal carcinoma.
Zheng D; Lai G; Chen Y; Yue Q; Liu X; Chen X; Chen W; Chan Q; Chen Y
J Magn Reson Imaging; 2018 Nov; 48(5):1208-1216. PubMed ID: 29693765
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy.
Pickles MD; Manton DJ; Lowry M; Turnbull LW
Eur J Radiol; 2009 Sep; 71(3):498-505. PubMed ID: 18572340
[TBL] [Abstract][Full Text] [Related]
50. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
[TBL] [Abstract][Full Text] [Related]
51. Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy.
Comes MC; Fanizzi A; Bove S; Didonna V; Diotiaiuti S; Fadda F; La Forgia D; Giotta F; Latorre A; Nardone A; Palmiotti G; Ressa CM; Rinaldi L; Rizzo A; Talienti T; Tamborra P; Zito A; Lorusso V; Massafra R
Comput Biol Med; 2024 Apr; 172():108132. PubMed ID: 38508058
[TBL] [Abstract][Full Text] [Related]
52. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
53. Difference of DCE-MRI Parameters at Different Time Points and Their Predictive Value for Axillary Lymph Node Metastasis of Breast Cancer.
Ya G; Wen F; Xing-Ru L; Zhuan-Zhuan G; Jun-Qiang L
Acad Radiol; 2022 Jan; 29 Suppl 1():S79-S86. PubMed ID: 33504446
[TBL] [Abstract][Full Text] [Related]
54. Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer.
Zhang J; Huang Y; Chen J; Wang X; Ma H
World J Surg Oncol; 2021 Sep; 19(1):284. PubMed ID: 34537053
[TBL] [Abstract][Full Text] [Related]
55. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.
Wu YC; Xiao ZB; Lin XH; Zheng XY; Cao DR; Zhang ZS
World J Gastroenterol; 2020 Oct; 26(39):6057-6073. PubMed ID: 33132655
[TBL] [Abstract][Full Text] [Related]
56. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.
An YY; Kim SH; Kang BJ; Lee AW
J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936
[TBL] [Abstract][Full Text] [Related]
57. Associations Between Dynamic Contrast Enhanced Magnetic Resonance Imaging and Clinically Relevant Histopathological Features in Breast Cancer: A Multicenter Analysis.
Surov A; Kim JY; Aiello M; Huang W; Yankeelov TE; Wienke A; Pech M
In Vivo; 2022; 36(1):398-408. PubMed ID: 34972741
[TBL] [Abstract][Full Text] [Related]
58. Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer.
Kato E; Mori N; Mugikura S; Sato S; Ishida T; Takase K
Jpn J Radiol; 2021 Aug; 39(8):791-801. PubMed ID: 33743147
[TBL] [Abstract][Full Text] [Related]
59. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
[TBL] [Abstract][Full Text] [Related]
60. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using radiomics of pretreatment dynamic contrast-enhanced MRI.
Yoshida K; Kawashima H; Kannon T; Tajima A; Ohno N; Terada K; Takamatsu A; Adachi H; Ohno M; Miyati T; Ishikawa S; Ikeda H; Gabata T
Magn Reson Imaging; 2022 Oct; 92():19-25. PubMed ID: 35636571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
